da Silva Cleide Gonçalves, Specht Anke, Wegiel Barbara, Ferran Christiane, Kaczmarek Elzbieta
Center for Vascular Biology Research and the Division of Vascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Circulation. 2009 Feb 17;119(6):871-9. doi: 10.1161/CIRCULATIONAHA.108.764571. Epub 2009 Feb 2.
Decreased endothelial nitric oxide (NO) synthase (eNOS) activity and NO production are critical contributors to the endothelial dysfunction and vascular complications observed in many diseases, including diabetes mellitus. Extracellular nucleotides activate eNOS and increase NO generation; however, the mechanism of this observation is not fully clarified.
To elucidate the signaling pathway(s) leading to nucleotide-mediated eNOS phosphorylation at Ser-1177, human umbilical vein endothelial cells were treated with several nucleotides, including ATP, UTP, and ADP, in the presence or absence of selective inhibitors. These experiments identified P2Y1, P2Y2, and possibly P2Y4 as the purinergic receptors involved in eNOS phosphorylation and demonstrated that this process was adenosine independent. Nucleotide-induced eNOS phosphorylation and activity were inhibited by BAPTA-AM (an intracellular free calcium chelator), rottlerin (a protein kinase Cdelta inhibitor), and protein kinase Cdelta siRNA. In contrast, blockade of AMP-activated protein kinase, calcium/calmodulin-dependent kinase II, calcium/calmodulin-dependent kinase kinase, serine/threonine protein kinase B, protein kinase A, extracellular signal-regulated kinase 1/2, and p38 mitogen-activated protein kinase did not affect nucleotide-mediated eNOS phosphorylation.
The present study indicates that extracellular nucleotide-mediated eNOS phosphorylation is calcium and protein kinase Cdelta dependent. This newly identified signaling pathway opens new therapeutic avenues for the treatment of endothelial dysfunction.
内皮型一氧化氮(NO)合酶(eNOS)活性降低和NO生成减少是许多疾病(包括糖尿病)中观察到的内皮功能障碍和血管并发症的关键因素。细胞外核苷酸可激活eNOS并增加NO生成;然而,这一现象的机制尚未完全阐明。
为了阐明导致核苷酸介导的eNOS在丝氨酸1177位点磷酸化的信号通路,在存在或不存在选择性抑制剂的情况下,用人脐静脉内皮细胞处理几种核苷酸,包括ATP、UTP和ADP。这些实验确定P2Y1、P2Y2以及可能的P2Y4为参与eNOS磷酸化的嘌呤能受体,并证明这一过程不依赖腺苷。核苷酸诱导的eNOS磷酸化和活性受到BAPTA-AM(一种细胞内游离钙螯合剂)、rottlerin(一种蛋白激酶Cδ抑制剂)和蛋白激酶Cδ小干扰RNA的抑制。相反,阻断AMP激活的蛋白激酶、钙/钙调蛋白依赖性激酶II、钙/钙调蛋白依赖性激酶激酶、丝氨酸/苏氨酸蛋白激酶B、蛋白激酶A、细胞外信号调节激酶1/2和p38丝裂原活化蛋白激酶并不影响核苷酸介导的eNOS磷酸化。
本研究表明,细胞外核苷酸介导的eNOS磷酸化依赖于钙和蛋白激酶Cδ。这一新发现的信号通路为治疗内皮功能障碍开辟了新的治疗途径。